Arabic Arabic English English French French German German
dark

Public Meeting on Patient Focused Drug Development for Alpha 1 Antitrypsin Part 1

On September 29, 2015, FDA hosted a public meeting on Patient-Focused Drug Development for Alpha-1 Antitrypsin. FDA was interested in obtaining patient perspectives on the impact of Alpha-1 Antitrypsin on daily life and patient views on treatment approaches. For more information, visit https://go.usa.gov/xHpRE.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Giving birth during the pandemic? Facts you need to know

Next Post

Willis Towers Watson offers sustainable investment framework

Related Posts
Total
0
Share